{"filing":{"accession_number":"0001104659-26-087891","cik":"0001133869","ticker":"CAPR","company_name":"CAPRICOR THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"capr-20260729x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm"},"events":[{"id":21499,"run_id":19391,"accession_number":"0001104659-26-087891","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure centers on two operational/regulatory developments: (1) publication of Phase 3 HOPE-3 trial results in The Lancet with an update to the LVEF statistical model (p-value revised from 0.04 to 0.09), and (2) completion of an FDA BIMO inspection with a Form 483 observation regarding documentation and vendor oversight. While the trial publication is a significant clinical milestone for a biotech company with a pending BLA (PDUFA target August 22, 2026), and the FDA inspection observation could signal regulatory risk, neither event fits the specific taxonomy categories. The statistical model revision is material to investors assessing the strength of the regulatory submission, but this is a clinical/operational disclosure rather than a restatement or going-concern issue. The BIMO observation, while potentially concerning, does not constitute a covenant breach, delisting risk, or other terminal event.","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21153,"accession_number":"0001104659-26-087891","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on two operational/regulatory developments: (1) publication of Phase 3 HOPE-3 trial results in The Lancet with an update to the LVEF statistical model (p-value revised from 0.04 to 0.09), and (2) completion of an FDA BIMO inspection with a Form 483 observation regarding documentation and vendor oversight. While the trial publication is a significant clinical milestone for a biotech company with a pending BLA (PDUFA target August 22, 2026), and the FDA inspection observation could signal regulatory risk, neither event fits the specific taxonomy categories. The statistical model revision is material to investors assessing the strength of the regulatory submission, but this is a clinical/operational disclosure rather than a restatement or going-concern issue. The BIMO observation, while potentially concerning, does not constitute a covenant breach, delisting risk, or other terminal event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T14:06:39.255217+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21153,"accession_number":"0001104659-26-087891","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on two operational/regulatory developments: (1) publication of Phase 3 HOPE-3 trial results in The Lancet with an update to the LVEF statistical model (p-value revised from 0.04 to 0.09), and (2) completion of an FDA BIMO inspection with a Form 483 observation regarding documentation and vendor oversight. While the trial publication is a significant clinical milestone for a biotech company with a pending BLA (PDUFA target August 22, 2026), and the FDA inspection observation could signal regulatory risk, neither event fits the specific taxonomy categories. The statistical model revision is material to investors assessing the strength of the regulatory submission, but this is a clinical/operational disclosure rather than a restatement or going-concern issue. The BIMO observation, while potentially concerning, does not constitute a covenant breach, delisting risk, or other terminal event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T14:06:39.255217+00:00","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-07-29"}]}